Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
April 30, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020

Axsome to host conference call and webcast on Friday, May 8, 2020 at 8:00 AM Eastern Time NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
April 27, 2020 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation

Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint) Demonstrated rapid and substantial...
April 06, 2020 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine

Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond mild intensity in 74% of...
March 30, 2020 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications

Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary...
March 20, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Randomizations concluded and trial participation in process of concluding to ensure patient safety during COVID-19 pandemic AXS-05 and placebo arms fully enrolled with estimated completion rate of...
March 12, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020 NDA filing for AXS-07 in migraine expected in 4Q 2020 Topline results for STRIDE-1 Phase 3 trial of AXS-05 in TRD on...
March 05, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer

NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
March 04, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

Axsome to host conference call and webcast on Thursday, March 12, 2020 at 8:00 AM Eastern Time NEW YORK, March 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
February 20, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...